胶质母细胞瘤再程放疗的现状与近期进展
本文综述胶质母细胞瘤(GBM)再程放疗的现状与进展。多数WHO IV级胶质瘤经手术加60 Gy/30次放疗并同步及辅助替莫唑胺后约2年内局部复发,复发后无标准治疗。立体定向放射外科(SRS)或立体定向放疗(SRT)的大分割或常规分割再程放疗有研究提示生存获益,但疗效与毒性仍待明确。
要点
- 复发GBM无标准治疗,再程放疗是可考虑的选择。
- SRS或SRT可采用大分割或常规分割方案实施再程照射。
- 多项研究提示再程放疗可能带来生存获益,但需权衡疗效与毒性。
核心结论
- 复发GBM缺乏标准治疗,再程放疗是可行手段,部分研究提示生存获益,但二次放疗的疗效与毒性仍有待明确。
研究设计与样本
- 本文为临床综述,概述GBM再程放疗的现状与近期进展,围绕患者选择、放疗技术、最佳剂量分割、脑组织再程放疗耐受性及放射性坏死风险展开讨论。
主要发现
- 尽管采用最大程度安全切除后外照射放疗(60 Gy/30次)联合同步及辅助替莫唑胺的积极治疗,约90%的WHO IV级胶质瘤(GBM)仍会在2年内局部复发。
- 使用SRS或SRT(大分割或常规分割方案)的若干研究提示,复发GBM患者再程放疗后可能有生存获益。
临床怎么用
- 再程放疗可用于复发GBM患者,需就患者选择、放疗技术及剂量分割进行个体化评估,并关注放射性坏死风险。
局限性
- 再程放疗的疗效与毒性尚存待回答的问题,复发GBM尚无标准治疗可供对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite aggressive management consisting of maximal safe surgical resection followed by external beam radiation therapy (60 Gy/30 fractions) with concomitant and adjuvant temozolomide, approximately 90% of WHO grade IV gliomas (glioblastomas, GBM) will recur locally within 2 years. For patients with recurrent GBM, no standard of care exists. Thanks to the continuous improvement in radiation science and technology, reirradiation has emerged as feasible approach for patients with brain tumors. Using stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT), either hypofractionated or conventionally fractionated schedules, several studies have suggested survival benefits following reirradiation of patients with recurrent GBM; however, there are still questions to be answered about the efficacy and toxicity associated with a second course of radiation. We provide a clinical overview on current status and recent advances in reirradiation of GBM, addressing relevant clinical questions such as the appropriate patient selection and radiation technique, optimal dose fractionation, reirradiation tolerance of the brain and the risk of radiation necrosis.
引用
- Minniti G, Niyazi M, Alongi F, et al. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol. 2021. PMID: 33602305. doi:10.1186/s13014-021-01767-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。